KR20120006554A - 항암 약물, 및 악성 흑색종 및 다른 암에 대한 용도 - Google Patents

항암 약물, 및 악성 흑색종 및 다른 암에 대한 용도 Download PDF

Info

Publication number
KR20120006554A
KR20120006554A KR1020117027765A KR20117027765A KR20120006554A KR 20120006554 A KR20120006554 A KR 20120006554A KR 1020117027765 A KR1020117027765 A KR 1020117027765A KR 20117027765 A KR20117027765 A KR 20117027765A KR 20120006554 A KR20120006554 A KR 20120006554A
Authority
KR
South Korea
Prior art keywords
cancer
compound
pharmaceutically acceptable
dimethylamino
diazenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020117027765A
Other languages
English (en)
Korean (ko)
Inventor
강가 라주 고카라주
슈드하카르 카시나
라마 라주 고카라주
벤카타 카나카 란가 라주 고카라주
벤카테스왈루 소메팔리
트리무르툴루 고라코티
키란 부파티라주
크리쉬아누 센굽타
벤카타 크리쉬나 라주 알루리
Original Assignee
카시나 라일라 이노바 파마슈티칼스 프라이빗 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 카시나 라일라 이노바 파마슈티칼스 프라이빗 리미티드 filed Critical 카시나 라일라 이노바 파마슈티칼스 프라이빗 리미티드
Publication of KR20120006554A publication Critical patent/KR20120006554A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
    • C07D253/04—1,2,3-Triazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D517/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having selenium, tellurium, or halogen atoms as ring hetero atoms
    • C07D517/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having selenium, tellurium, or halogen atoms as ring hetero atoms in which the condensed system contains three hetero rings
    • C07D517/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
KR1020117027765A 2009-04-27 2010-04-26 항암 약물, 및 악성 흑색종 및 다른 암에 대한 용도 Ceased KR20120006554A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN959/CHE/2009 2009-04-27
IN959CH2009 2009-04-27

Publications (1)

Publication Number Publication Date
KR20120006554A true KR20120006554A (ko) 2012-01-18

Family

ID=42992332

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020117027765A Ceased KR20120006554A (ko) 2009-04-27 2010-04-26 항암 약물, 및 악성 흑색종 및 다른 암에 대한 용도

Country Status (11)

Country Link
US (1) US8143237B2 (enExample)
EP (1) EP2424351B1 (enExample)
JP (1) JP5571168B2 (enExample)
KR (1) KR20120006554A (enExample)
CN (1) CN102438449B (enExample)
AU (1) AU2010243213B2 (enExample)
BR (1) BRPI1006651A2 (enExample)
CA (1) CA2759519A1 (enExample)
IL (1) IL215789A0 (enExample)
NZ (1) NZ595602A (enExample)
WO (1) WO2010125575A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230067281A (ko) 2021-11-09 2023-05-16 공주대학교 산학협력단 항암 활성을 갖는 인데노피라졸론 유도체 화합물, 그의 제조방법 및 그의 용도

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9090633B2 (en) 2010-11-18 2015-07-28 Kasina Laila Innova Pharmaceuticals Private Limited Substituted 4-(arylamino) selenophenopyrimidine compounds and methods of use thereof
CN103221048A (zh) 2010-11-18 2013-07-24 卡斯纳莱拉创新药物私人有限公司 取代的4-(硒吩-2(或3)-基氨基)嘧啶化合物及其使用方法
AU2011340063B2 (en) * 2010-12-09 2016-03-24 Kasina Laila Innova Pharmaceuticals Private Limited Substituted 4-(arylamino) selenophenopyrimidine compounds and methods of use thereof
WO2012176212A1 (en) 2011-06-20 2012-12-27 V.B. Medicare Pvt. Ltd. Carrier based nanogel formulation for skin targeting.
KR101418776B1 (ko) 2011-09-28 2014-07-14 사회복지법인 삼성생명공익재단 셀레노펜-접합 방향족 화합물, 및 이의 제조 방법
CN103906742A (zh) * 2011-09-28 2014-07-02 世宗大学校产学协力团 硒吩稠合芳族化合物和其制备方法
WO2014012074A2 (en) 2012-07-12 2014-01-16 Euclises Pharmaceuticals, Inc. No-releasing nonoate (nitrogen-bound) sulfonamide-linked-coxib anti-cancer agents
US9044464B2 (en) 2012-07-12 2015-06-02 Euclises Pharmaceuticals, Inc. No-releasing guanidine-coxib anti-cancer agents
US9505765B2 (en) 2012-07-26 2016-11-29 Confluence Life Sciences Inc. 4-alkoxy/aralkoxy-5-substituted-pyrrolopyrimidine compounds as TAK1 inhibitors in disease treatment
US20140199728A1 (en) 2013-01-14 2014-07-17 Amgen Inc. Methods of using cell-cycle inhibitors to modulate one or more properties of a cell culture
WO2016118951A2 (en) 2015-01-23 2016-07-28 Confluence Life Sciences, Inc. Heterocyclic itk inhibitors for treating inflammation and cancer
CN108129475A (zh) * 2018-02-08 2018-06-08 中南大学湘雅三医院 一种生物光敏剂及其制备方法和应用
WO2025005748A1 (ko) * 2023-06-29 2025-01-02 (주)아이젠사이언스 신규 셀레노펜 유도체

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6620804B2 (en) * 1996-06-03 2003-09-16 Purdue Research Foundation Selenophene anti-tumor agents
DE69724472T2 (de) * 1996-06-03 2004-06-17 Purdue Research Foundation, West Lafayette Selenophen-antitumormittel
WO2008016664A2 (en) * 2006-08-02 2008-02-07 University Of Massachusetts Lowell Compositions and methods for treating cancer with dacarbazine nanoemulsions
WO2010029577A2 (en) * 2008-09-15 2010-03-18 Ganga Raju Gokaraju Anti-cancer drugs and uses relating thereto for metastatic malignant melanoma and other cancers

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230067281A (ko) 2021-11-09 2023-05-16 공주대학교 산학협력단 항암 활성을 갖는 인데노피라졸론 유도체 화합물, 그의 제조방법 및 그의 용도

Also Published As

Publication number Publication date
CN102438449B (zh) 2014-06-18
EP2424351A1 (en) 2012-03-07
EP2424351A4 (en) 2013-04-03
AU2010243213A1 (en) 2011-10-27
JP2012525329A (ja) 2012-10-22
US8143237B2 (en) 2012-03-27
CA2759519A1 (en) 2010-11-04
AU2010243213B2 (en) 2014-09-11
JP5571168B2 (ja) 2014-08-13
NZ595602A (en) 2013-05-31
US20100272678A1 (en) 2010-10-28
CN102438449A (zh) 2012-05-02
BRPI1006651A2 (pt) 2015-08-25
WO2010125575A1 (en) 2010-11-04
IL215789A0 (en) 2012-01-31
EP2424351B1 (en) 2015-10-21
HK1166591A1 (en) 2012-11-02

Similar Documents

Publication Publication Date Title
KR20120006554A (ko) 항암 약물, 및 악성 흑색종 및 다른 암에 대한 용도
US10954193B2 (en) Substituted indole Mcl-1 inhibitors
AU2009290365B2 (en) Anti-cancer drugs and uses relating thereto for metastatic malignant melanoma and other cancers
CN103080112B (zh) 吲嗪衍生物，其制备方法及其治疗用途
CN101663033B (zh) 作为smo拮抗剂的三唑衍生物
KR20040004705A (ko) 카스파제의 활성제 및 아폽토시스의 유도제로서의 치환된3-아릴-5-아릴-[1,2,4]-옥사디아졸과 유사체 및 이의 용도
KR101921764B1 (ko) 피라졸로-퀴놀린
US8658664B2 (en) Cyclopamine tartrate salt and uses thereof
US10106554B2 (en) 7-(morpholinyl)-2-(N-piperazinyl) methyl thieno [2, 3-C] pyridine derivatives as anticancer drugs
CN111943960B (zh) 取代的嘧啶二酮类化合物及其用途
US9278958B2 (en) Anti-cancer compounds
TW200403991A (en) NF-κb inhibitors
JP2008530053A (ja) 癌の治療のための抗増殖性剤としてのテトラヒドロピリドチオフェン
HK1166591B (en) Anti-cancer drugs, and uses relating for malignant melanoma and other cancers
US10689384B2 (en) Imidazo[1,2-a]quinoxalines and derivatives thereof for the treatment of cancer
JP2020536848A (ja) Ｉｌ−１２産生の刺激による癌の治療
HK1154863A (en) Anti-cancer drugs and uses relating thereto for metastatic malignant melanoma and other cancers
HK1236949B (en) 7-(morpholinyl)-2-(n-piperazinyl) methyl thieno [2, 3-c] pyridine derivatives as anticancer drugs
HK1236949A1 (en) 7-(morpholinyl)-2-(n-piperazinyl) methyl thieno [2, 3-c] pyridine derivatives as anticancer drugs

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20111122

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20150421

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20160201

Patent event code: PE09021S01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20160816

Patent event code: PE09021S01D

PE0601 Decision on rejection of patent

Patent event date: 20161130

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20160816

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

Patent event date: 20160201

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I